Cite
Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone.
MLA
Kanao, Kent, et al. “Efficacy of Abiraterone Acetate for High-Risk Hormone-Naïve Metastatic Prostate Cancer: A Comparison with Combined Androgen Blockade Therapy with Bicalutamide and Androgen Deprivation Therapy Alone.” PLoS ONE, vol. 17, no. 10, Oct. 2022, pp. 1–9. EBSCOhost, https://doi.org/10.1371/journal.pone.0276081.
APA
Kanao, K., Takahashi, T., Umezawa, Y., Okabe, T., Kaneko, G., Shirotake, S., Nishimoto, K., & Oyama, M. (2022). Efficacy of abiraterone acetate for high-risk hormone-naïve metastatic prostate cancer: A comparison with combined androgen blockade therapy with bicalutamide and androgen deprivation therapy alone. PLoS ONE, 17(10), 1–9. https://doi.org/10.1371/journal.pone.0276081
Chicago
Kanao, Kent, Takayuki Takahashi, Yuta Umezawa, Takashi Okabe, Go Kaneko, Suguru Shirotake, Koshiro Nishimoto, and Masafumi Oyama. 2022. “Efficacy of Abiraterone Acetate for High-Risk Hormone-Naïve Metastatic Prostate Cancer: A Comparison with Combined Androgen Blockade Therapy with Bicalutamide and Androgen Deprivation Therapy Alone.” PLoS ONE 17 (10): 1–9. doi:10.1371/journal.pone.0276081.